Injectable Drug Delivery News

  1. Catalent And Bhami Research Laboratory Enter Into Licensing Agreement For Technology To Deliver High-Concentration Biologics Subcutaneously 3/16/2023

    Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies.

  2. PCI Pharma Services Expands Biologics Leadership With New Center Of Excellence Facility In The Midwest 3/15/2023

    PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced plans for a new 200,000-square-foot facility in Rockford, Illinois to enhance the organization’s capacity in injectable drug-device combination product assembly of both biologics and small molecules.

  3. Aenova Introduces New Sterile Strategy 3/10/2023

    Aenova Group, a leading international contract developer and manufacturer for the pharmaceutical and healthcare industries, presents its new sterile strategy. In the future, the focus in sterile production will be on expanding the sterile site in Latina (Italy). There, portfolio and capacities are being expanded, especially in the area of prefilled syringes (PFS) as well as intramammary syringes.

  4. Marchesini Group Acquires Milan-Based Company M.A.R. S.p.A. 3/8/2023

    A new company is joining Marchesini Group. The latest arrival is M.A.R. S.p.A., a company from Lainate (Milan) specialised in the construction of machinery for packaging liquids and powders in glass and plastic bottles, syringes, carpules and other containers for the pharmaceutical industry. This operation further extends the array of technologies available to Marchesini Group for the packaging of products in the Pharma world.

  5. eXmoor Pharma And Vaccine Developer Imophoron Sign Process Development Partnership 2/22/2023

    eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and Imophoron, the developer of a novel, next generation thermostable vaccine platform, ADDomer, to combat present and future infectious diseases, today announce the signature of a strategic process development partnership that includes a future GMP manufacturing route.

  6. CDMO Dalton Pharma Services Announces Major Expansion With New Filling And Lyophilization Technology 2/16/2023

    Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility to fill vials, syringes, and cartridges under isolator technology.

  7. Windgap Medical Appoints Aaron Mann As CEO, Michael Samar As CFO 2/13/2023

    Both bring significant industry tenure and experience to their roles, and with Windgap Co-Founder Brent Buchine, will lead the company's continued growth in the field of complex injectable drug delivery solutions.

  8. Elektrofi Announces Collaboration With Thermo Fisher Scientific To Strengthen Manufacturing Capabilities For Future Clinical Trials 2/7/2023

    Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, today announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.

  9. Phillips-Medisize Expands Product Portfolio With Launch Of A Pen Injector Platform Designed To Lower Pharma Costs, Risks And Market Barriers 2/1/2023

    Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, has expanded its product portfolio with the introduction of a disposable pen injector.

  10. Lilly Plans To Invest Additional $450M At Manufacturing Site In Research Triangle Park 1/24/2023

    Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly's incretin products that treat diabetes.